ストックスクリーナーアプリを入手
4.01
0.25%
0.010
アフターアワーズ：
4.00
-0.010
-0.25%
Design Therapeutics Inc (DSGN) 最新ニュース
Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight - The Malaysian Reserve
Nuveen Asset Management LLC Sells 54,550 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Two Sigma Investments LP Trims Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Millennium Management LLC Acquires New Shares in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Design Therapeutics starts Friedreich ataxia patient trial By Investing.com - Investing.com South Africa
Transcript : Design Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 02 - marketscreener.com
RBC Capital maintains Design Therapeutics stock rating with $5 target By Investing.com - Investing.com South Africa
RBC Capital maintains Design Therapeutics stock rating with $5 target - Investing.com India
Design Therapeutics starts Friedreich ataxia patient trial - Investing.com
Design Therapeutics Announces Start Of Friedreich Ataxia Patient Dosing Ex-U.S. In Its Restore-Fa Phase 1/2 Multiple-Ascending Dose Trial Of Dt-216P2 - marketscreener.com
Design Therapeutics, Inc. Reports Initial Safety Data for DT-216P2 in Friedreich Ataxia Trial Amid FDA Clinical Hold on U.S. IND Application - Nasdaq
Design Therapeutics Achieves First Patient Dosing in Friedreich Ataxia Trial, Faces FDA Hurdle - Stock Titan
ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Bank of America Corp DE Sells 556,157 Shares of Aegon Ltd. (NYSE:AEG) - Defense World
40,289 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by BNP Paribas Financial Markets - Defense World
Clinical-Stage Biotech Design Therapeutics Set for Major Jefferies Healthcare Conference Presentation - Stock Titan
Autodesk (NASDAQ:ADSK) Price Target Raised to $376.00 at Citigroup - Defense World
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
As Gold Pushes Higher, Junior Miners Begin to Show Signs of Life - The Globe and Mail
Palantir vs. IBM: The Breakthrough Wall Street Is Missing - The Globe and Mail
Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail
Northern Trust Corp Purchases 51,351 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
3 Penny Stocks With Market Caps As Low As $70M To Watch - Yahoo Finance
Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox - Genetic Engineering and Biotechnology News
Promontory Therapeutics Announces Successful End of Phase 2 Meeting with US FDA on Phase 3 Registrational Study Design for PT-112 in Patients with Metastatic Castration-Resistant Prostate Cancer - PR Newswire
Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Holdings Increased by Dimensional Fund Advisors LP - Defense World
Leerink Partnrs Analysts Lower Earnings Estimates for DSGN - The AM Reporter
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference - The Manila Times
Quantum Sandbox Act: Why These 3 Quantum Stocks Could Be Ready to Explode - The Globe and Mail
Q2 EPS Forecast for Design Therapeutics Reduced by Analyst - Defense World
Chardan Capital Issues Optimistic Forecast for CRSP Earnings - Defense World
FY2025 EPS Estimates for EYPT Decreased by Cantor Fitzgerald - Defense World
Wells Fargo & Company MN Boosts Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
FY2025 Earnings Forecast for GPCR Issued By Leerink Partnrs - Defense World
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - The Globe and Mail
Ataxia Pipeline: Advancing Therapeutics and 32+ Leading - openPR.com
Barclays PLC Has $639,000 Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results - The Manila Times
Design Therapeutics Inc Files For Mixed Shelf Of Up To $300 MillionSEC Filing - marketscreener.com
Design Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Design Therapeutics, Inc. SEC 10-Q Report - TradingView
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter ... - Bluefield Daily Telegraph
Invesco Ltd. Buys New Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
AI Proteins to Present Key Advances in Miniprotein Therapeutics Development at PEGS Boston 2025 - Business Wire
Friedreich's Ataxia Market Growth | Trends, Treatments & - openPR.com
Design Therapeutics reports positive outcomes from trial of DT-168 eye drops - Yahoo Finance
Design Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated' - marketscreener.com
Design Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025 - Nasdaq
Design Therapeutics (DSGN) Reveals Positive Phase 1 Trial Results for DT-168 | DSGN Stock News - GuruFocus
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy - The Manila Times
JPMorgan Chase & Co. Buys 48,528 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PR Newswire
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):